<DOC>
	<DOCNO>NCT00937781</DOCNO>
	<brief_summary>RATIONALE : Studying sample tumor tissue patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor predict patient respond treatment . PURPOSE : This research study look tumor tissue sample patient melanoma treat clinical trial EST-1690 .</brief_summary>
	<brief_title>Study Tumor Tissue From Patients With Melanoma Treated Clinical Trial EST-1690</brief_title>
	<detailed_description>OBJECTIVES : - To validate prognostic role several biomarkers suggest gene expression profile tissue microarray ( TMA ) study ( e.g. , NCOA3 , SPP1 , RGS1 ) outcome associate melanoma EST-1690 cohort use IHC analysis . - To examine potential predictive role biomarkers patient undergo adjuvant interferon alfa therapy . - To analyze correlation intensity biomarker expression survival cohort observation interferon-treated group . - To examine prognostic role biomarkers outcome associate melanoma EST-1690 cohort use quantitative-PCR . - To isolate RNA primary specimen patient enrol EST-1690 cohort ass expression gene suggest cDNA microarray IHC analyse ( e.g. , NCOA3 , SPP1 , RGS1 ) prognostic predictive marker . OUTLINE : Samples EST-1690 cohort obtain analyzed several biomarkers ( i.e. , NCOA3 , SPP1 , RGS1 ) via immunohistochemistry quantitative PCR . RNA isolate specimen assess gene expression via quantitative PCR .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis melanoma No metastatic disease diagnosis Treated protocol EST1690 Primary tumor tissue specimens available PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>